sxRNA Cell-Targeting Technology
Answering Long-Standing Obstacles in RNA Therapeutics
How RNA-Based Therapy Drugs Act
RNA-based Therapeutics act like blueprints. They instruct your cells to make a protein encoded in the RNA.
Current mRNA Therapeutics are always ‘ON,’ meaning that the RNA is converted (translated) into protein in any cell the RNA enters.
Understanding Our Technology: A Simple "Lock & Key" Mechanism Allowing for Precision Delivery
sxRNA Technologies Inc. has invented structurally interacting RNA (sxRNA) which can ‘LOCK’ and ‘UNLOCK’ the activity of the RNA therapeutic, so it is active only in targeted cells.
We do this by creating RNA structures from two-pieces of RNA, which control the activity of the drug. One piece is embedded in the RNA drug (the Lock) and the other (the Key) is uniquely present in the cells being targeted. Only when the two pieces of RNA come together does the drug becomes active.
We control where within the body the RNA therapeutic is "unlocked."
We can control which cells express the protein encoded by the RNA Therapeutic. This control is possible for any inserted RNA. As long as the trigger appears only in the cells of interest, they can be uniquely targeted. With non-targeted cells unable to "unlock" the mRNA, sxRNA aims to decrease the amount and severity of side effects for RNA therapeutics.
sxRNA has created a platform that allows us to make RNA-based therapeutics act only in specific, targeted cells...
...which was not previously possible.
sxRNA Technologies as a Platform
sxRNA taps into unique RNA "keys" specific to different tissues and cancers, offering a versatile platform with the potential to target and treat a wide range of diseases. By unlocking these RNA signatures, sxRNA enables precision therapies tailored to specific cell types and conditions.
Organoid Kits
Tools for researchers studying neurodegenerative diseases.
In parallel, we are also developing an sxRNA-based Neuronal Organoid Kit to be used by researchers and pharmaceutical companies studying age-related dementias and for screening and developing new Alzheimer’s drugs.
Alzheimer’s Disease
Eliminating senescent brain cells
Through our STTR small business development grant, funded by the NIH/National Institute on Aging, we are using sxRNA technology to eliminate senescent (old, dysfunctional) cells that accumulate in the brains of Alzheimer’s patients and influence the neighboring healthy tissue. As our ‘Key,’ we are targeting unique small RNAs (called microRNAs) expressed only in these senescent cells.
Antiviral Treatments
Selectively targeting Epstein-Barr Virus infected cells
The sxRNA platform demonstrates a significant increase in antiviral activity, showing a ~20-fold higher efficacy in Epstein-Barr Virus-infected cells compared to non-infected cells. This targeted approach highlights the platform’s potential in selectively addressing viral infections, offering a promising pathway for developing more precise antiviral therapies.
Work with
to push our platform forward
Working with us means actively pushing forward the opportunities with our proprietary technology platform. We are eager to work with you!
